SURVIVAL AND PROGNOSTIC FACTORS OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MALAYSIA

Loading...
Thumbnail Image
Date
2012-07
Authors
ERNEST, MANGANTIG
Journal Title
Journal ISSN
Volume Title
Publisher
Pusat Pengajian Sains Perubatan Universiti Sains Malaysia
Abstract
Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) activities for acute myeloid leukemia (AML) patients in Malaysia have increased in recent years, yet limited studies have report their survival and prognostic factors. The research findings obtained are expected to help to identify patients that most benefit from the treatment. Objectives: To determine the overall survival probabilities and identify prognostic factors of death among AML patients treated with HSCT in Malaysia. Methods: A retrospective record review was conducted on 300 AML patients treated with allogeneic HSCT in Malaysia that registered at the Blood and Bone Marrow Transplant Registry, National Transplant Registry during the years from 1987 to 2010. Kaplan-Meier Product Limit Estimates, Simple and Multiple Cox regression were performed to determine the statistically significant prognostic factors of mortality among the AML patients in Malaysia. Results: The 10-year overall survival probability of AML patients treated with allogeneic HSCT in Malaysia was 63.1% (95% Confidence Interval: 56.8, 68.6). The 10-year overall survival probabilities were found to be significantly different in performance score, marrow status at transplant, source of stem cells, donor type and graft-versus-host disease prophylaxis. The significant prognostic factors that were identified in this study were female donor (Adjusted Hazard Ratio=1.71; 95% CI: 1.10, 2.66; p value=0.016), marrow status second complete remission or beyond (Adjusted HR=2.00; 95% CI: 1.16, 3.46; p value=0.013), marrow status refractory (Adjusted HR=4.66; 95% CI: 2.40, 9.06; p value<0.001) and conditioning intensity nonmyeloablative (Adjusted HR=1.91; 95% CI: 1.21, 3.01; p value=0.005). Conclusion: AML patients who were treated with allogeneic HSCT in Malaysia were shown to have good overall survival rate. Thus, HSCT could be the standard option for suitable patients. Donor’s sex, marrow status and conditioning intensity were the important prognostic factors of death among the AML patients treated with HSCT in Malaysia.
Description
Keywords
Medical Statistics
Citation